Combination desensitization therapy with anti-CD40 mAb, belatacept, and bortezomib in a sensitized, maximally major histocompatibility complex (MHC)-mismatched, DSA positive, NHP model found prolonged graft survival and decreased risk of graft loss due to AMR, but increased cytomegalovirus (CMV) infections [64]. Here, CD40 is linked to cytomegalovirus infection.